HIV Infections Clinical Trial
— FAME-HOfficial title:
Food as Medicine for HIV: A Randomized Trial of Medically Tailored Meals and Lifestyle Intervention
This is a single-site, open-label, Phase II, community-based randomized controlled explanatory trial to test the efficacy of a medically tailored meal + intensive lifestyle intervention (MTM + ILI) intervention for adults with food insecurity, HIV, and T2DM or high risk of T2DM, compared with a group that receives usual MTM.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | February 2027 |
Est. primary completion date | August 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria - Male or female - Diagnosis of HIV - Diagnosis of Type 2 Diabetes Mellitus or high risk for type 2 diabetes mellitus, defined as meeting CDC eligibility criteria for the diabetes prevention program. Specifically, an individual without a diagnosis of T2DM must 1) have had a blood test result in the prediabetes range within the past year (Hemoglobin A1C: 5.7-6.4% OR Fasting plasma glucose: 100-125 mg/dL OR Two-hour plasma glucose [after a 75 g glucose load]: 140-199 mg/dL), 2) Have been previously diagnosed with gestational diabetes, OR 3) have a high-risk result (score of 5 or higher) on the Prediabetes Risk Test (https://www.cdc.gov/prediabetes/pdf/Prediabetes-Risk-Test-Final.pdf) - Experiencing food insecurity as indicated by 2-item Hunger Vital Sign - English speaking - Aged =18 years - BMI = 23 kg/m2 - No plans to move from the area for at least 1 year - Free living to the extent that participant has control over dietary intake - Willing and able to provide written informed consent and participate in all study activities Exclusion Criteria: - Participant in diabetes, nutrition, or weight research intervention in last 12 months - Current AIDS defining illness - Another family member or household member is a study participant. Only one member of each household may take part in this study. - Considering bariatric surgery in the next year or prior bariatric surgery in the past 2 years - Lack of safe, stable residence and ability to store meals - Lack of telephone - Pregnancy/breastfeeding or intended pregnancy in the next year - History of malignancy, other than non-melanoma skin cancer, unless surgically or medically cured > 5 years ago or in remission. Patients with localized prostate and breast cancer diagnosed during the course of routine screening will not be excluded. - Advanced kidney disease (estimated creatinine clearance < 30 ml/min) - Known drug or alcohol misuse in the past 6 months - Known psychosis or major psychiatric illness that prevents participation with study activities - Intermittent use of medications (e.g., oral or intravenous glucocorticoids) that are likely to affect blood sugar |
Country | Name | City | State |
---|---|---|---|
United States | University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
University of North Carolina, Chapel Hill | Community Servings, Massachusetts General Hospital, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Food Insecurity Score at Month 6 | Food Insecurity Score. Score ranges from 0-10, with higher scores indicating greater food insecurity. | 6 Months | |
Other | Food Insecurity Score at Month 12 | Food Insecurity Score. Score ranges from 0-10, with higher scores indicating greater food insecurity. | 12 Months | |
Other | Food Insecurity Score at Month 18 | Food Insecurity Score. Score ranges from 0-10, with higher scores indicating greater food insecurity. | 18 Months | |
Other | Systolic Blood Pressure at Month 6 | Systolic blood pressure in mm Hg | 6 Months | |
Other | Systolic Blood Pressure at Month 12 | Systolic blood pressure in mm Hg | 12 Months | |
Other | Systolic Blood Pressure at Month 18 | Systolic blood pressure in mm Hg | 18 Months | |
Other | Diastolic Blood Pressure at Month 6 | Diastolic blood pressure in mm Hg | 6 Months | |
Other | Diastolic Blood Pressure at Month 12 | Diastolic blood pressure in mm Hg | 12 Months | |
Other | Diastolic Blood Pressure at Month 18 | Diastolic blood pressure in mm Hg | 18 Months | |
Other | Diet Quality Score at Month 6 | Diet Quality as assessed by Brief Dietary Assessment Scale. This score is comprised of 3 sections (or subscales) used to assess dietary patterns. Subscales are scored independently. The subscales are: Vegetables, Fruit, Whole Grains, and Beans subscale (range 0 - 20), Drinks, Desserts, Snacks, Eating Out, and Salt subscale (range 0- 20), and Fish, Meat, Poultry, Dairy, and Eggs subscale (range 0-10): Total score equals the sum of the 3 subscales. For subscales and total score, higher scores indicates better diet quality. | 6 months | |
Other | Diet Quality Score at Month 12 | Diet Quality as assessed by Brief Dietary Assessment Scale. This score is comprised of 3 sections (or subscales) used to assess dietary patterns. Subscales are scored independently. The subscales are: Vegetables, Fruit, Whole Grains, and Beans subscale (range 0 - 20), Drinks, Desserts, Snacks, Eating Out, and Salt subscale (range 0- 20), and Fish, Meat, Poultry, Dairy, and Eggs subscale (range 0-10): Total score equals the sum of the 3 subscales. For subscales and total score, higher scores indicates better diet quality. | 12 months | |
Other | Diet Quality Score at Month 18 | Diet Quality as assessed by Brief Dietary Assessment Scale. This score is comprised of 3 sections (or subscales) used to assess dietary patterns. Subscales are scored independently. The subscales are: Vegetables, Fruit, Whole Grains, and Beans subscale (range 0 - 20), Drinks, Desserts, Snacks, Eating Out, and Salt subscale (range 0- 20), and Fish, Meat, Poultry, Dairy, and Eggs subscale (range 0-10): Total score equals the sum of the 3 subscales. For subscales and total score, higher scores indicates better diet quality. | 18 months | |
Other | Cost-Related Medication Underuse at Month 6 | Any affirmative response to cost-related medication underuse items | 6 months | |
Other | Cost-Related Medication Underuse at Month 12 | Any affirmative response to cost-related medication underuse items | 12 months | |
Other | Cost-Related Medication Underuse at Month 18 | Any affirmative response to cost-related medication underuse items | 18 months | |
Other | Adherence to Refills and Medications Scale-Diabetes (ARMS-D) Medication Adherence Score at Month 6 | Medication Adherence as assessed by 7-item ARMS-D scale. Scores range from 7 to 28, with higher scores indicating more problems with adherence. | 6 months | |
Other | ARMS-D Medication Adherence Score at Month 12 | Medication Adherence as assessed by 7-item ARMS-D scale. Scores range from 7 to 28, with higher scores indicating more problems with adherence. | 12 months | |
Other | ARMS-D Medication Adherence Score at Month 18 | Medication Adherence as assessed by 7-item ARMS-D scale. Scores range from 7 to 28, with higher scores indicating more problems with adherence. | 18 months | |
Other | Diabetes Self-Care Activities Medication Adherence Score at Month 6 | Medication Adherence as assessed by 1-item summary of diabetes self-care activities measure. Scores range from 0-7 with higher scores indicating better adherence. | 6 months | |
Other | Diabetes Self-Care Activities Medication Adherence Score at Month 12 | Medication Adherence as assessed by 1-item summary of diabetes self-care activities measure. Scores range from 0-7 with higher scores indicating better adherence. | 12 months | |
Other | Diabetes Self-Care Activities Medication Adherence Score at Month 18 | Medication Adherence as assessed by 1-item summary of diabetes self-care activities measure. Scores range from 0-7 with higher scores indicating better adherence. | 18 months | |
Other | Diet Self-Efficacy Score at Month 6 | Diet Self-Efficacy as assessed by cardiac diet self-efficacy scale. Scores range from 16 to 80 with higher scores indicating greater self-efficacy. | 6 months | |
Other | Diet Self-Efficacy Score at Month 12 | Diet Self-Efficacy as assessed by cardiac diet self-efficacy scale. Scores range from 16 to 80 with higher scores indicating greater self-efficacy. | 12 months | |
Other | Diet Self-Efficacy Score at Month 18 | Diet Self-Efficacy as assessed by cardiac diet self-efficacy scale. Scores range from 16 to 80 with higher scores indicating greater self-efficacy. | 18 months | |
Other | Perceived Diabetes Self-Management Self-Efficacy Score at Month 6 | Diabetes Self-Efficacy as assessed by Perceived Diabetes Self-Management Scale. Scores range from 8 to 40 with higher scores indicating greater self-efficacy | 6 months | |
Other | Perceived Diabetes Self-Management Self-Efficacy Score at Month 12 | Diabetes Self-Efficacy as assessed by Perceived Diabetes Self-Management Scale. Scores range from 8 to 40 with higher scores indicating greater self-efficacy | 12 months | |
Other | Perceived Diabetes Self-Management Self-Efficacy Score at Month 18 | Diabetes Self-Efficacy as assessed by Perceived Diabetes Self-Management Scale. Scores range from 8 to 40 with higher scores indicating greater self-efficacy | 18 months | |
Other | Stress Score at 6 months | Stress as assessed by perceived stress scale. Scores range from 0 to 40 with higher scores indicating higher perceived stress. | 6 months | |
Other | Stress Score at 12 months | Stress as assessed by perceived stress scale. Scores range from 0 to 40 with higher scores indicating higher perceived stress. | 12 months | |
Other | Stress Score at 18 months | Stress as assessed by perceived stress scale. Scores range from 0 to 40 with higher scores indicating higher perceived stress. | 18 months | |
Other | Food/Medication Trade-offs at Month 6 | Single item-indicators of trading off medication for food or food for medication. An affirmative response indicates the presence of a trade-off. | 6 months | |
Other | Food/Medication Trade-offs at Month 12 | Single item-indicators of trading off medication for food or food for medication. An affirmative response indicates the presence of a trade-off. | 12 months | |
Other | Food/Medication Trade-offs at Month 18 | Single item-indicators of trading off medication for food or food for medication. An affirmative response indicates the presence of a trade-off. | 18 months | |
Other | Cluster of Differentiation 4 (CD4+) Count at Month 6 | CD4+ Count | 6 Months | |
Other | Self-Reported CD4+ Count at Month 6 | Self-Reported CD4+ Count | 6 Months | |
Other | Self-Reported CD4+ Count at Month 12 | Self-Reported CD4+ Count | 12 Months | |
Other | Self-Reported CD4+ Count at Month 18 | Self-Reported CD4+ Count | 18 Months | |
Other | HIV Viral Load at Month 6 | HIV Viral Load | 6 Months | |
Other | Self-Reported HIV Viral Load at Month 6 | Self-Reported HIV Viral Load | 6 Months | |
Other | Self-Reported HIV Viral Load at Month 12 | Self-Reported HIV Viral Load | 12 Months | |
Other | Self-Reported HIV Viral Load at Month 18 | Self-Reported HIV Viral Load | 18 Months | |
Other | C-Reactive Protein (CRP) at Month 6 | C-Reactive Protein | 6 months | |
Primary | Bodyweight at Month 6 | Bodyweight measured in Kg | 6 months | |
Secondary | Bodyweight at Month 12 | Bodyweight measured in Kg | 12 months | |
Secondary | Bodyweight at Month 18 | Bodyweight measured in Kg | 18 months | |
Secondary | Hemoglobin A1c at Month 6 | Hemoglobin A1c Level | 6 months | |
Secondary | Hemoglobin A1c at Month 12 | Hemoglobin A1c Level | 12 months | |
Secondary | Hemoglobin A1c at Month 18 | Hemoglobin A1c Level | 18 months | |
Secondary | Health-Related Quality of Life Score as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS)-29 at Month 6 | The PROMIS-29 includes seven health related quality of life domains (Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain), and the pain domain has two subdomains (interference and intensity). Raw scores, except pain intensity, are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on physical function indicates better functioning, whereas a higher score on depression indicates more severe depressive symptoms. Will report overall score and scores for each domain. From these data will also calculate a PROMIS-Preference (PROPr score) (PROPr scores range from -0.022 (worst) to 1.0 (best)). | 6 months | |
Secondary | Health-Related Quality of Life Score as assessed by PROMIS-29 at Month 12 | The PROMIS-29 includes seven health related quality of life domains (Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain), and the pain domain has two subdomains (interference and intensity). Raw scores, except pain intensity, are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on physical function indicates better functioning, whereas a higher score on depression indicates more severe depressive symptoms. Will report overall score and scores for each domain. From these data will also calculate a PROMIS-Preference (PROPr score) (PROPr scores range from -0.022 (worst) to 1.0 (best)). | 12 months | |
Secondary | Health-Related Quality of Life Score as assessed by PROMIS-29 at Month 18 | The PROMIS-29 includes seven health related quality of life domains (Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain), and the pain domain has two subdomains (interference and intensity). Raw scores, except pain intensity, are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on physical function indicates better functioning, whereas a higher score on depression indicates more severe depressive symptoms. Will report overall score and scores for each domain. From these data will also calculate a PROMIS-Preference (PROPr score) (PROPr scores range from -0.022 (worst) to 1.0 (best)). | 18 months | |
Secondary | Depressive Symptom Score at Month 6 | Depressive Symptoms as assessed by PROMIS Short Form (PROMIS SF) v1.0 - Depression 4a. Raw scores are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on depression indicates more severe depressive symptoms. | 6 months | |
Secondary | Depressive Symptom Score at Month 12 | Depressive Symptoms as assessed by PROMIS SF v1.0 - Depression 4a. Raw scores are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on depression indicates more severe depressive symptoms. | 12 months | |
Secondary | Depressive Symptom Score at Month 18 | Depressive Symptoms as assessed by PROMIS SF v1.0 - Depression 4a. Raw scores are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on depression indicates more severe depressive symptoms. | 18 months | |
Secondary | Diabetes Distress Score as assessed by Problem Areas in Diabetes (PAID)-11 at Month 6 | Score ranges from 11-55 with higher scores indicating greater diabetes distress | 6 months | |
Secondary | Diabetes Distress Score as assessed by PAID-11 at Month 12 | Score ranges from 11-55 with higher scores indicating greater diabetes distress | 12 months | |
Secondary | Diabetes Distress Score as assessed by PAID-11 at Month 18 | Score ranges from 11-55 with higher scores indicating greater diabetes distress | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |